Effect of Hearing Aid Labeling on Speech Understanding Measures: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Effect of Hearing Aid Labeling on Speech Understanding Measures (NCT05274178), a non-randomized na study. The primary outcome is Quick Speech in Noise Test (QuickSIN).

2. Clinical Question

The question is about measured performance under two labeling conditions, not whether one type of hearing aid is generally superior. The same participants were intended to use both labeled devices in the same test session, making the comparison within-participant in concept. However, the record identifies the allocation as nonrandomized and does not report the order of device testing or how the labels were presented to participants. Those details matter when considering whether the recorded contrast can be attributed to labeling rather than other differences in testing conditions or device use.

3. Trial Design

The registry describes a completed, single-masking, nonrandomized crossover study sponsored by Sonova AG. It lists enrollment of 20 and a study start date of 2022-05-26, with primary completion on 2022-06-16. The phase is listed as not applicable. The study is classified as other rather than as a drug trial.

Participants were divided by prior hearing-aid experience into naive listeners and experienced users. Naive listeners were defined as people who had never worn a hearing aid. Experienced users were defined as people with at least six months of hearing-aid experience. Each group was to be tested with both Audeo P devices, one labeled OTC and one labeled Prescriptive. Both were generically programmed for mild to moderate hearing loss. The registry describes the primary outcome population as participants tested with both labels in the same session.

A crossover design allows measurements under more than one condition in the same participant. In general, this can make the comparison sensitive to within-person differences, while also making test order, learning, fatigue, and carryover important considerations. The record does not report the order in which the labeled devices were tested, whether order was balanced, or how potential order effects were handled. It states that the allocation was nonrandomized; therefore, the comparison should not be read as a randomized, like-for-like control comparison.

The record reports one primary outcome measure and two analyses, but does not describe the statistical methods used for those analyses. A rationale for the enrollment target, a sample-size justification, and the identity of the person or people masked are not reported in the registry record. These omissions limit what can be concluded about how the study was planned and how the results were analyzed.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: All participants who were tested with the devices labeled as "OTC" and with devices that were labeled as "Prescriptive" in the same test session.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Quick Speech in Noise Test (QuickSIN), measured over Day 1 of 1 day study.

The primary endpoint was the Quick Speech in Noise Test (QuickSIN), reported in decibels (dB). In this test, a participant repeats sentences presented against background noise at varying levels. The result represents the signal-to-noise level at which the participant can repeat 50% of the words correctly. A lower score indicates better speech-in-noise perception.

This type of measure is used to quantify speech understanding under noisy listening conditions, rather than relying only on a general impression of hearing. The endpoint description explains the scale: a score of 0 dB means speech and noise are at the same level when the participant correctly repeats half the words, while a score of 6 dB means the speech needs to be louder than the noise by that amount for the same word-recognition level. These are examples in the registry’s description, not study-arm results.

The reported timeframe is Day 1 of a 1 day study. The registry says that scores in this study ranged from +2 to +18 dB. It does not provide the separate score distribution or summary for either label, nor the within-participant contrast. Consequently, the range alone does not reveal whether scores tended to be lower with one label, how variable scores were within either condition, or how precisely any comparison was estimated.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Interpreting a clinical comparison requires both a clear outcome definition and a suitable estimate of the contrast between conditions. The registry defines QuickSIN and explains the meaning of its score direction, but does not report the condition-level results or the statistical analysis used to compare them. The general concepts below explain what such analyses would usually address; they do not describe methods confirmed for this study.

What does a paired comparison address?

When the same participant is measured under two conditions, a paired analysis uses the within-person difference rather than treating the two sets of measurements as unrelated. This can be useful because stable characteristics of a participant are shared across the two measurements. The estimated effect would summarize how scores differ between the labels, and its uncertainty would reflect variation in those within-person differences. For this study, the registry says participants were tested with both labels in the same session, but does not report whether the analysis used paired differences or how incomplete pairs, if any, were handled.

A confidence interval is a range of values compatible with the observed data and the assumptions of the analysis. It communicates precision as well as direction: a narrow interval indicates a more precise estimate than a wide one. A p-value addresses how inconsistent the data are with a specified null hypothesis under the model’s assumptions; it does not measure the size or practical importance of an effect. Neither a confidence interval nor a p-value for the label comparison is reported in the registry record.

Why do design details matter?

Crossover comparisons can be affected by sequence and period effects. A period effect is a change associated with when a condition is measured; a sequence effect can arise when the order of conditions differs. Learning the speech-in-noise task, fatigue, or residual effects from a prior condition are general examples of factors that might influence repeated testing. These possibilities do not establish that an effect occurred in this study. The record does not state device order, whether order was balanced, whether there was a washout period, or whether any such factors were included in an analysis.

Nonrandom allocation also matters. Random allocation is one way to make condition assignment less dependent on participant characteristics or other influences. Here, the record explicitly identifies allocation as nonrandomized. The device labels were both tested, but details about assignment, presentation, and masking are limited. The resulting comparison should therefore be interpreted according to the actual study procedures, which are not fully described in the registry record, rather than assumed to have the protections of a randomized comparison.

How should outcome variation be understood?

Variation describes how much measurements differ across participants or repeated observations. A summary such as a mean needs a measure of spread to show whether values cluster near that summary or vary widely. The registry provides a full-range dispersion description and reports that scores ranged from +2 to +18 dB, but it does not report the summary values or spread separately by label. The full range alone cannot establish the typical score or the uncertainty of a contrast.

In general, over-dispersion means that observed variability is greater than a statistical model expects. If a model assumes less variability than is present, its uncertainty estimates can be too small and its confidence intervals too narrow. Whether over-dispersion is relevant depends on the outcome and analysis model. The registry does not report a model, a diagnostic assessment, or an adjustment for over-dispersion, so no claim about its presence or handling is possible for this study.

What does the planning illustration mean?

The registry’s planning description characterizes its sample-size illustration as based on the observed effect, not as the trial’s own design. It describes a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the target effect expressed as a fraction of the observed effect. For non-time-to-event outcomes, such illustrations are expressed as participants per arm. The calculated planning values are not reported in the registry entries used for this explanation, and the illustration should not be mistaken for the rationale behind enrollment of 20.

Such calculations are hypothetical planning exercises. They estimate the sample size associated with stated assumptions; they do not establish the probability that the completed study detected an effect. In particular, they are not observed power. A planning calculation based on an observed effect may also depend strongly on the estimated effect and its uncertainty. The registry does not report the trial’s sample-size justification, the assumed effect used in its original planning, or an interim-analysis plan.

What is missing from the analysis description?

The record lists two analyses but does not describe their models, covariates, estimands, handling of repeated measures, or inferential procedures. An estimand is the precise treatment or condition contrast the analysis is intended to estimate, including the population and outcome being summarized. Clear reporting of these elements helps readers understand what a result means and which observations contributed. In their absence, the statistical approach and the relationship between the two analyses are not reported in the registry record.

These general principles help distinguish what the study design suggests from what the posted information establishes. The record establishes that two labeled devices were tested and identifies the endpoint scale and range. It does not establish the comparative estimate, its uncertainty, or the methods used to obtain it.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists one primary outcome measure and two analyses. It does not explain what the two analyses addressed, whether they concerned separate experience groups or other contrasts, or whether one was designated primary. The analysis hypotheses and any plan for controlling the risk of false-positive findings across multiple tests are not reported in the registry record.

Multiplicity is the general issue that arises when several outcomes, contrasts, subgroups, or analyses are examined. The more questions analyzed, the greater the opportunity for a chance finding unless the analysis plan accounts for that multiplicity. This does not mean that the two analyses necessarily created a problem; their purpose and relationship are not stated. A correction or other multiplicity strategy is not reported.

Missing-data procedures are also not described. The registry does not report whether any QuickSIN observations were missing, how missing measurements were handled, or whether participants without complete measurements were included in an analysis. The endpoint population is described as participants tested under both labels in the same session, but that description does not establish the completeness of the outcome data.

The analysis populations, any exclusions after enrollment, and the handling of protocol deviations are not reported in the registry record. Nor does it describe an intention-to-treat or per-protocol approach. These details are important because analysis populations can affect the interpretation of a comparison, especially when the design relies on measurements from the same participant under both conditions. No assumptions about missingness, exclusions, or analysis-set membership can be made from the information recorded.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry reports serious adverse events, other adverse events, and deaths separately for naive listeners and experienced users. For each group, the recorded number at risk is 10 for the serious-event and other-event entries, and the number affected is 0 for both categories. Deaths are also recorded as 0 in each group. No serious adverse event terms are listed.

These figures describe what the registry reports for the listed groups; they do not establish that no event could occur outside the recorded observation or reporting period. The record does not specify the adverse-event observation window, the method of collection, or whether event reporting was actively solicited. It also does not state whether adverse events were assessed separately by device label or across the study as a whole.

A zero count in the registry means no affected participants were recorded in that category for the listed group. It is not proof that the underlying risk is zero. The available figures should be read as descriptive safety reporting in this study, not as a comparative safety estimate between the OTC-labeled and Prescriptive-labeled devices.

12. What the Result Does, and Does Not, Mean

The registry record establishes that a completed nonrandomized crossover study tested hearing aids carrying OTC and Prescriptive labels and used QuickSIN as its primary outcome. The endpoint measures speech recognition in background noise, with lower scores representing better performance. The recorded score range was +2 to +18 dB. These details clarify what was measured and how to read the scale.

The record does not report the QuickSIN results separately for the two labels or the estimated contrast between them. It therefore does not show whether scores were higher, lower, or similar under either label. There is also no reported confidence interval or p-value for the comparison, so the precision and statistical uncertainty of any difference cannot be assessed. The outcome range cannot substitute for those missing summaries.

The study’s crossover structure means both labels were intended to be tested in participants in the same session. That feature is relevant to the comparison, but the allocation is explicitly nonrandomized. The registry does not report test order, masking details beyond single masking, or an analysis that accounts for within-participant measurements. The results should not be interpreted as if they came from a randomized comparison or as if potential order effects had been excluded.

The findings also cannot be generalized from the registry description to all hearing-aid users or all devices. The studied devices were Audeo P hearing aids, generically programmed for mild to moderate hearing loss, and participants were divided into naive listeners and experienced users. Subgroup-specific outcome estimates and broader population details are not reported.

In short, the record describes the study question, population, design, and outcome scale, but does not report the comparative outcome evidence needed to characterize the observed label contrast. It supports an account of what was measured, not a conclusion that one labeling condition led to better or worse speech-in-noise scores.

13. Why This Trial Matters Statistically

This study raises a statistical question about how a labeling condition relates to performance when the same participants are tested with two devices. The crossover arrangement makes within-person comparison conceptually relevant: each participant can serve as a reference for their own measurement under the other label. That structure can reduce the influence of characteristics that remain stable within a participant, provided the analysis and study procedures appropriately address repeated measurements.

At the same time, this is recorded as a nonrandomized study. Random allocation is not the only issue in a crossover comparison, but the absence of randomization makes careful description of assignment and testing procedures especially important. Order, practice, fatigue, and carryover are general statistical and design considerations for repeated testing. The registry does not report how these issues were managed, so readers cannot assess their potential influence.

The endpoint also illustrates why a scale’s direction and summary matter. QuickSIN scores are interpretable in decibels, with lower values indicating better speech-in-noise perception. Yet knowing the scale and the range is not enough to estimate a contrast. Condition-specific summaries and a measure of uncertainty are needed to judge the size and precision of the comparison. Those comparative results are not reported in the registry record.

Finally, the record lists two analyses while giving limited information about their purpose and methods. This emphasizes the value of reporting which comparisons were planned, how repeated observations were analyzed, and how missing data and multiple analyses were handled. Without such detail, the study can be described, but its statistical evidence for the labeling question cannot be evaluated from the registry record alone.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important limitation for interpreting the primary question is that the registry record does not report condition-specific QuickSIN results or an estimate comparing the two device labels. It gives the overall score range, +2 to +18 dB, but not the distribution, summary, or uncertainty within either condition. The direction and size of the observed contrast therefore cannot be established from the reported endpoint information.

The study is identified as nonrandomized, and the registry does not report the order in which participants used the two labeled devices. It also does not state whether order was balanced or whether potential practice, fatigue, or carryover effects were addressed. These are relevant considerations for a crossover design, although the record does not establish that any such effect occurred.

Single masking is recorded, but the masked party or parties are not identified. The description does not state whether participants knew the device labels during testing, how the labels were presented, or whether the evaluator was masked. Those implementation details are important when the comparison itself concerns labeling.

The registry lists two analyses but does not describe their purpose, model, or inferential methods. It does not report handling of missing measurements, analysis populations, exclusions, or multiplicity. A sample-size justification and an interim-analysis plan are also not reported in the registry record. The recorded enrollment does not by itself explain the basis for the study’s size or the precision of its comparison.

Finally, the record describes Audeo P devices generically programmed for mild to moderate hearing loss and includes naive listeners and experienced users. It does not report subgroup results or additional population details that would support broader generalization. These limitations concern what can be concluded from the registry entry; they do not establish that unreported procedures or analyses were absent from the study itself.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Effect of Hearing Aid Labeling on Speech Understanding Measures — NCT05274178.
• Registry record last updated 2023-07-10; status last verified 2023-06.
• Results first posted 2023-07-10.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT05274178 is a completed, nonrandomized crossover study sponsored by Sonova AG. The registry lists enrollment of 20, a study start date of 2022-05-26, and primary completion on 2022-06-16. It describes naive listeners and experienced hearing-aid users tested with Audeo P devices labeled OTC and Prescriptive.

The primary outcome was QuickSIN score in decibels, measured on Day 1 of a 1 day study. Lower scores indicate better speech-in-noise perception, and the record reports a score range of +2 to +18 dB. It lists one primary outcome measure and two analyses. Comparative scores, an effect estimate, and statistical uncertainty are not reported in the registry record.

For both experience groups, the registry records 0 serious adverse events, 0 other adverse events, and 0 deaths. The event observation period and the statistical analysis details are not reported.